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A B S T R A C T
Opioid painkillers are a promising treatment for chronic breathlessness, but are associated with potentially fatal
side eﬀects. In the treatment of breathlessness, their mechanisms of action are unclear. A better understanding
might help to identify safer alternatives. Learned associations between previously neutral stimuli (e.g. stairs)
and repeated breathlessness induce an anticipatory threat response that may worsen breathlessness,
contributing to the downward spiral of decline seen in clinical populations. As opioids are known to inﬂuence
associative learning, we hypothesized that they may interfere with the brain processes underlying a conditioned
anticipatory response to breathlessness in relevant brain areas, including the amygdala and the hippocampus.
Healthy volunteers viewed visual cues (neutral stimuli) immediately before induction of experimental
breathlessness with inspiratory resistive loading. Thus, an association was formed between the cue and
breathlessness. Subsequently, this paradigm was repeated in two identical neuroimaging sessions with
intravenous infusions of either low-dose remifentanil (0.7 ng/ml target-controlled infusion) or saline
(randomised).
During saline infusion, breathlessness anticipation activated the right anterior insula and the adjacent
operculum. Breathlessness was associated with activity in a network including the insula, operculum,
dorsolateral prefrontal cortex, anterior cingulate cortex and the primary sensory and motor cortices.
Remifentanil reduced breathlessness unpleasantness but not breathlessness intensity. Remifentanil
depressed anticipatory activity in the amygdala and the hippocampus that correlated with reductions in
breathlessness unpleasantness. During breathlessness, remifentanil decreased activity in the anterior insula,
anterior cingulate cortex and sensory motor cortices. Remifentanil-induced reduction in breathlessness
unpleasantness was associated with increased activity in the rostral anterior cingulate cortex and nucleus
accumbens, components of the endogenous opioid system known to decrease the perception of aversive stimuli.
These ﬁndings suggest that in addition to eﬀects on brainstem respiratory control, opioids palliate
breathlessness through an interplay of altered associative learning mechanisms. These mechanisms provide
potential targets for novel ways to develop and assess treatments for chronic breathlessness.
Introduction
Breathlessness debilitates millions of people with cardiorespiratory
disease, terminal cancer and neuromuscular disorders. Chronic breath-
lessness often correlates poorly with objective measures of disease
severity (Hayen et al., 2013; Herigstad et al., 2011; Lansing et al.,
2009). This poor correlation between breathlessness and disease
markers might be explained by interindividual variability in brain
processing of respiratory sensations, hence the justiﬁcation for neu-
roimaging studies. Breathlessness is considered a multidimensional
symptom, including sensory components of 'work of breathing',
aﬀective and emotional components of breathlessness sensations
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(Hayen et al., 2013; Lansing et al., 2009) compounded by the various
psychological processes associated with an individual's suﬀering
(Hayen et al., 2013; Oxley and Macnaughton, 2016).
There has been growing interest in the use of low-dose opioids for
the treatment of chronic breathlessness (Ekstrom et al., 2015; Rocker
et al., 2013). The neural mechanisms of opioid-driven breathlessness
relief are largely unknown (Peiﬀer, 2011). Opioids depress respiration
by acting upon brainstem respiratory centres (Pattinson, 2008) and
also act in higher brain centres involved in respiratory control
(Pattinson et al., 2009). Importantly, in experimental settings low-
dose opioids have been shown to diﬀerentially act on the “unpleasant-
ness" (a component of the aﬀective dimension) compared to the
"intensity" (a component of the sensory dimension) of aversive stimuli
(Price et al., 1985).
Over repeated episodes of breathlessness, associations are formed
between previously neutral stimuli, e.g. a ﬂight of stairs (conditioned
stimulus [CS]) and breathlessness (unconditioned stimulus [US] (De
Peuter et al., 2004)). This has two important outcomes: ﬁrstly, learnt
breathlessness anticipation may increase breathlessness itself (De
Peuter et al., 2005), reinforcing the CS-US pairing, and secondly, the
feared activity is avoided, fuelling a downward spiral of activity
avoidance, physical deconditioning and worsening breathlessness.
In this context of conditioned learning, opioids have shown
profound eﬀects on association learning and memory formation to
aversive experiences (Sandkühler and Lee, 2013; Fanselow 1998;
McNally 2004). Two of the key structures involved in these processes
are the amygdala and hippocampus (Phelps, 2004). As these structures
are rich in opioid receptors (Favaroni Mendes 2008; McGaraughty and
Heinricher, 2002), we hypothesised that opioid eﬀects on association
learning with regards to breathlessness are mediated, at least in part,
by the amygdala and hippocampus.
Therefore, the eﬀect of opioids on breathlessness most likely stems
from multiple actions within the central nervous system. A better
understanding of these brain mechanisms could be used to develop
alternative therapies with fewer safety concerns than opioids
(Pattinson, 2015; Ray et al., 2016; Robertson et al., 2016; Vozoris
et al., 2016). In the present study we used functional neuroimaging to
identify the neural correlates of the conditioned response to breath-
lessness and their modulation by the mu-opioid receptor agonist
remifentanil. We tested the hypothesis that in addition to direct
eﬀects on respiration, remifentanil would also act on neural mechan-
isms associated with conditioned learning in the amygdala and
hippocampus.
Methods
This double-blind, randomized, placebo-controlled mechanistic
study investigated the neural correlates of the opioid remifentanil
upon the anticipation and perception of breathlessness. An aversive
delay-conditioning session was followed by two FMRI sessions (remi-
fentanil or saline placebo, counterbalanced across participants). The
sessions were performed on three consecutive days at the same time
each day.
Data acquisition
Participants
Data from 19 healthy participants (10 females, age 24 ( ± 7 SD)
years) was analysed in this study. Written informed consent was
obtained in accordance with the Oxfordshire Research Ethics
Committee. Although 29 participants originally participated, 10 were
excluded for the following reasons: 2 participants exhibited vasovagal
syncope during cannulation; 1 participant did not comply with study
instructions; 4 participants did not learn the association between visual
cues and respiratory stimuli; 3 participants were excluded because of
technical diﬃculties with the MRI equipment. Participants were right-
handed non-smokers and had no history of neurological (including
painful conditions), pulmonary or cardiovascular disease, were free
from acute respiratory infections and were currently not receiving any
medication. Participants fasted solids for 6 h and liquids for 2 h before
every session.
Initial session
The Center for Epidemiologic Studies Depression Scale (CES-D;
(Radloﬀ, 1977)) was used to identify (and exclude) participants with
clinical depression. The trait scale of the Spielberger State-Trait
Anxiety Inventory (STAI; (Spielberger, 2010)) was used to characterize
general participant anxiety.
Breathlessness stimulus
The breathlessness stimulus used in this study was intermittent
resistive inspiratory loading for 30–60 s administered via the MRI
compatible breathing system illustrated in Supplementary Fig. 1.
Manually operated hydraulic valves diverted inspiratory ﬂow via one
of three routes that either did not restrict breathing, or provided a mild
or strong resistive load. Expiration was unrestricted via a one-way
valve (Hans Rudolph, Shawnee, Kansas, USA).
In an externally cued delay conditioning paradigm (Fig. 1), parti-
cipants learned associations between three visual cues (conditioned
stimuli, (CS), either a white square, star or triangle shape presented on
a black background) and resistive inspiratory loading that was inter-
mittently applied to induce three diﬀerent respiratory sensations
(unconditioned stimuli, (US), either breathlessness (strong inspiratory
load, approximately −12 cm H2O), a mild inspiratory load (approxi-
mately −3 cm H2O) or no inspiratory load). The pairing between the
visual cue (CS) and respiratory load (US) was maintained constant for
each participant during all 3 experimental sessions, but was counter-
balanced between participants. Four repeats of each of the mild load
and strong load (breathlessness) and eight repeats of the unloaded
condition were performed. Immediately after each inspiratory load,
Fig. 1. Schematic illustration of experimental session and aversive conditioning paradigm. Prior to the application of each inspiratory load, the ﬁxation cross on the screen changed to
one of three shapes, a triangle, a square and a star to signal the imminent application of a stimulus (mild inspiratory load, strong inspiratory load) for eight seconds (anticipation period).
The shape remained on the screen during the application of the stimulus (stimulus period) for 30–60 s and changed back to the ﬁxation cross when the stimulus ceased. The shapes were
counterbalanced across participants. Each inspiratory load was followed by an unloaded period of between 30 and 60 s that was indicated by a third visual cue. The use of relatively long
breathlessness stimuli was chosen to maximize the emotional responses associated with anticipation of breathlessness. Participants rated their respiratory intensity and unpleasantness
after each stimulus. Visual stimuli were generated and presented in white on a black background using the Cogent toolbox (www.vislab.ucl.ac.uk/Cogent/) for MatLab (MathWorks Inc.,
Natick, MA, USA).
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participants rated the intensity and unpleasantness of their breathing
on a horizontal visual analogue scale (VAS) with the anchors ‘no
breathlessness’ on the left and ‘severe breathlessness’ on the right for
intensity ratings and ‘not unpleasant’ on the right and ‘extremely
unpleasant’ on the left for unpleasantness ratings. Bond-Lader mood
values of tension-relaxation, sedation-alertness, and discontentment-
contentment (Bond and Lader, 1974) were obtained immediately
following the breathlessness protocol using visual analogue scales
(VAS) displayed on the screen and a button box.
Conscious association between CS and US was conﬁrmed in writing
and 4 participants who did not form such associations were excluded
from the study. Following the breathlessness protocol, an anaesthetist
performed a medical assessment; this included a 20-minute test
infusion of remifentanil to ensure tolerance and safety.
The participants were allowed at least 5 min to get accustomed to
the breathing system before the experiment commenced. Throughout
the experiment, the partial pressure of expired carbon dioxide
(PETCO2) was maintained constant (isocapnia). This was achieved by
initially increasing PETCO2 by +0.3 kPa from baseline by adding CO2 to
the inspired air, and then manually adjusting inspired CO2 as necessary
(Hayen et al., 2015; Wise et al., 2007). The partial pressure of expired
oxygen (PETO2) was kept constant at 20 kPa in a similar manner.
Physiological recordings
Arterial oxygen saturation and heart rate were monitored continu-
ously and non-invasive blood pressure was recorded before and after
each scan (In Vivo Research, Orlando, FL, USA). PETCO2 and PETO2
were determined using rapidly responding gas analysers
(ADinstruments ML206) and continuously displayed and recorded
with a data acquisition device (PowerLab 8, AD instruments,
Colorado Springs, CO, USA) connected to a laptop computer using
dedicated software (Chart 5, AD instruments, Colorado Springs, CO,
USA). Inspiratory gas ﬂow was measured with a pneumotachograph
(ADinstruments Spirometer FE141) and a standard ﬂow head. Mouth
pressure was measured using a Validyne pressure transducer (Validyne
Engineering, 8626 Wilbur Ave Northridge, CA 91324).
FMRI sessions
Two FMRI sessions were performed, one on each of the two days
following the initial conditioning session, and consisted of a remifen-
tanil and saline placebo session (counterbalanced). During acquisition
of the FMRI scans, participants underwent the breathlessness protocol
as described above (identical to the initial session). Additional struc-
tural scans, ﬁeld maps and measures of cerebral blood ﬂow were
obtained (described in detail below).
Drug infusion
A target-controlled infusion (TCI) pump (Graseby 3500 TCI
incorporating Diprisor, SIMS Graseby Ltd, Watford, UK) delivered
remifentanil (at a solution concentration of 10 μg/ml) to achieve a
desired eﬀect site concentration of 0.7 ng/ml or saline placebo
(administered in the same manner) intravenously into a cannula placed
in the dorsum of the left hand. The TCI pump was pre-programmed
with the three-compartment pharmacokinetic model of remifentanil
(Minto et al., 1997a, 1997b). The total duration of the infusion was
45 min, which allowed for a 10-min ramp-up period to reach the
desired eﬀect site concentration. All participants fasted for 6 h before
each visit and were monitored for an hour after termination of the
infusion.
Both study participants and study experimenters were blinded to
the order of drug administration, with only the administering anaes-
thetist and the MRI scanner operator being aware of drug condition.
We used remifentanil as a model opioid because its pharmacoki-
netics and pharmacodynamics are ideal for a mechanistic volunteer
study such as this. It is a synthetic μ-opioid agonist with a rapid onset
of action, a context sensitive half-life of 3–4 min, and an elimination
half-life of approximately 8–10 min. This means that the drug has
extremely rapid onset and oﬀset, and when combined with a target-
controlled infusion, drug levels can be easily manipulated within a
short time frame. Due to its rapid onset and oﬀset, remifentanil needs
to be administered as an intravenous infusion and when this infusion is
combined with a pharmacokinetic model of its action, it is possible to
manipulate plasma and eﬀect site (brain) concentrations in a pre-
dictable and consistent manner. Using a target controlled infusion
allows a constant drug eﬀect to be maintained throughout the experi-
ment.
In terms of volunteer safety, if adverse eﬀects develop, the infusion
can be terminated, with the knowledge that the drug will wear oﬀ
within minutes. We chose to deliver an eﬀect site concentration of
0.7 ng/ml based upon our extensive clinical and experimental experi-
ence with this drug (Bingel et al., 2011; MacIntosh et al., 2008; Mitsis
et al., 2009; Pattinson et al., 2008; Wanigasekera et al., 2011, 2012;
Wise et al., 2002, 2004). Although direct comparison of equivalence
with other opioids (e.g. oral morphine) is diﬃcult, we chose a dose that
is at the lower end of eﬃcacy for the treatment of acute pain but which
has previously been shown to have eﬀects on respiration (Mitsis et al.,
2009) and pain suppression (Bingel et al., 2011). We would estimate
that the eﬀect site concentration of 0.7 ng/ml would represent the
analgesia oﬀered by 4–7 mg oral (or 2.0–3.5 mg intravenous) mor-
phine used to treat low-moderate pain. Remifentanil is ultra-short
acting, and this means that when given as a bolus the eﬀects would vary
within the scanning session, making it diﬃcult to dissociate primary
drug eﬀect from secondary eﬀects such as raised PETCO2. For this
reason, comparison with studies employing bolus doses of remifentanil
(Leppa et al., 2006) is diﬃcult.
MRI data acquisition
MRI data were acquired on a 3 T Siemens Trio scanner using a 32-
channel head coil. A whole-brain gradient echo, echo-planar-imaging
(EPI) sequence, repetition time (TR)=3000 ms, echo time (TE)=30 ms,
ﬁeld of view: 192×192 mm, voxel size 3×3×3 mm, 45 slices, 380
volumes) was used for functional scans. Fieldmaps were obtained
using a symmetric-asymmetric spin-echo sequence before the baseline
functional scans (30 ms echo time, 0.5494 ms dwell time, ﬁeld of view
and matrix identical to EPI) and were used to correct for magnetic ﬁeld
inhomogeneities. A T1-weighted structural (MPRAGE sequence,
TR=1720 ms, TE=4.68 ms, ﬂip angle 8°, voxel size 1×1×1 mm) image
was acquired for functional image registration.
To account for changes in cerebral blood ﬂow (CBF) induced by
remifentanil (MacIntosh et al., 2008), a multi-inversion time pseudo-
continuous arterial spin labeling sequence (multi-TI PCASL; Tis = 1.65,
1.9, 2.15, 2.4, 2.65, 2.9 s, TI cycles = 6, tag duration –1.4 s,
TR=4000 ms, TE=13 ms, voxel size 3.8×3.8×5.0 mm, 24 slices, 72
volumes) was run either before or after the BOLD scanning (breath-
lessness experiment) randomised between participants whilst the
drug/placebo infusion was running. This included phase contrast
measurement of blood velocity in the carotid arteries.
Data analysis
Behavioural ratings
Behavioural data were analysed in SPSS (Version 21, IBM Corp.,
Armonk, NY). Separate 2 [drug: saline vs. remifentanil] ×2 [stimula-
tion condition: normal breathing vs. strong loading] repeated measures
ANOVAs were performed for ratings of perceived intensity and
unpleasantness. The three dimensions of the Bond-Lader mood scale
(alertness-sedation, relaxation-tension and contentment-discontent-
ment) were compared in three separate 2 [drug: saline vs. remifentanil]
×2 [time: during and 15 min after infusion] repeated measures
ANOVAs using Bonferroni adjustments within tests. Diﬀerences be-
tween saline and remifentanil ratings of intensity and unpleasantness
of unmodiﬁed breathing and breathlessness were tested using a one-
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tailed, paired t-test, based on the extensive literature surrounding the
analgesic actions of acutely administered opioids. Diﬀerences in
intensity and unpleasantness scores were also correlated with diﬀer-
ences in sedation, tension and discontentment between saline and
remifentanil with Bonferroni corrections for multiple comparisons.
Questionnaires were scored according to their respective manuals.
Physiological data
Physiological recordings were exported to MatLab (MathWorks
Inc., Natick, MA, USA) and analysed using custom-written scripts.
FMRI analysis
Image pre-processing
FMRI data processing was carried out using FEAT (FMRI Expert
Analysis Tool) Version 6.00, part of FSL (FMRIB's Software Library,
www.fmrib.ox.ac.uk/fsl), using a whole-brain approach. Pre-processing
of the data was performed with MCFLIRT motion correction
(Jenkinson et al., 2002), non-brain removal using BET (Smith,
2002), spatial smoothing using a full-width-half-maximum Gaussian
kernel of 5 mm, and high pass temporal ﬁltering (Gaussian-weighted
least-squares straight line ﬁtting, with sigma=75.0 s) with 150 s cut-oﬀ.
Registration to the high resolution structural was carried out using
boundary-based-registration (BBR; FSL software library), registration
from high resolution structural to standard space was then further
reﬁned using nonlinear registration (FNIRT; FSL software library).
The FMRI scans were corrected for motion, scanner and cerebro-
spinal ﬂuid artefacts using independent component analysis (ICA)
denoising (Kelly et al., 2010). BOLD images were corrected for
physiological noise with physiological noise modelling integrated in
FSL (RETROICOR) (Brooks et al., 2008; Harvey et al., 2008). The noise
signal determined by RETROICOR was adjusted for interactions with
the ICA denoising to ensure artefactual signal was not reintroduced
through the combination of both noise correction techniques (Faull
et al., 2016). This is described in detail below.
Further details of physiological noise correction
To ensure noise was not reintroduced through the combination of
ICA denoising and RETROICOR, the following stepwise process was
followed:
1. ICA was used to decompose FMRI data into diﬀerent spatial and
temporal components using FSL's MELODIC (Multivariate
Exploratory Linear Optimised Decomposition into Independent
Components) using automatic dimensionality estimation. This is a
data-driven Bayesian approach to ICA dimensionality estimation
that allows MELODIC to choose the number of components into
which the FMRI data is decomposed. This means that diﬀerent
FMRI scans may be decomposed into a diﬀerent number of
components. The noise components (classiﬁed as movement, cere-
bral spinal ﬂuid (CSF) and scanner artefact) were then identiﬁed
based on spatial location of signal and signal frequency (Griﬀanti
et al., 2014; Salimi-Khorshidi et al., 2014), and manually removed
from the 4D FMRI data. This is referred to as the "ICA denoised
data".
2. The pulse oximetry and respiratory ﬂow measurements allowed
determination of cardiac and respiratory phase with each acquired
slice of each FMRI image volume. This assigned phase is then
entered into a low-order Fourier expansion (Brooks et al., 2013;
Harvey et al., 2008) to derive time course regressors (2 cardiac, 2
respiratory and 1 interaction regressor). These regressors explain
potential signal changes associated with cardiac and respiratory (or
interacting) processes. These regressors were regressed against the
ICA denoised data using FSL's Physiological Noise Modelling (PNM)
tool (Brooks et al., 2008; Harvey et al., 2008). The residuals from
this regression were subtracted from the ICA denoised data. This is
referred to as the "PNM signal".
3. To combine the ICA denoising with PNM it is necessary to remove
any overlap between the two. Therefore the PNM signal was also run
through ICA denoising (Griﬀanti et al., 2014; Salimi-Khorshidi et al.,
2014) and the resulting denoised PNM signal was removed from the
ICA denoised data to give the ﬁnal denoised data used in the
analysis.
Statistical analysis
An overview of the statistical analysis is depicted in Supplementary
Fig. 2.
First level analysis
Linear models were used to describe the data. The ﬁrst level
analysis used a general linear modelling (GLM) approach with multiple
explanatory variables (EVs). Individual subject contrasts were gener-
ated for mild and strong anticipation periods from the beginning of the
symbol presentation until the onset of the inspiratory resistive loading.
‘On’ loading periods for each of the mild and strong stimuli were then
constructed from the onset of the resistance stimulus until the end of
the loading period. Unloaded periods were modelled for the duration of
the unloaded stimulus. Periods when participants rated their preceding
sensations and the 5-s periods after each respiratory manipulation
(ﬁxation cross; presented to give participants a chance to recover
before giving their subjective ratings) were modelled as regressors of
no interest. PETCO2 was entered as a separate EV in order to account
for residual ﬂuctuations in CO2 that could aﬀect BOLD signal (Wise
et al., 2007).
To account for possible changes in the haemodynamic response
function (HRF), including slice-timing delays, external timing ﬁles
were convolved with an optimal basis set of three waveforms (FLOBS:
FMRIB's Linear Optimal Basis Sets, default FLOBS supplied in FSL
(Woolrich et al., 2004a)), instead of the standard gamma waveform.
The second and third FLOBS waveforms, which model the temporal
and dispersion derivatives, were orthogonalised to the ﬁrst waveform,
of which the parameter estimate was then passed up to the higher level
to be used in the group analysis.
Saline analysis
Firstly, a higher-level mixed eﬀects analysis was conducted to
obtain group average results during the saline condition only.
FMRIB's Local Analysis of Mixed Eﬀects (FLAME 1+2 (Woolrich
et al., 2004b)) was used to process images with automatic outlier de-
weighting, and a univariate analysis of the group mean was performed.
Analysis was corrected for multiple comparisons across the whole
brain. A cluster threshold of > 2.3 and a corrected cluster signiﬁcance
threshold of p=0.05 were used.
Remifentanil-saline diﬀerence analysis
The diﬀerence between saline and remifentanil conditions was
calculated using a two-step higher level approach. In a second-level
analysis, the eﬀects of remifentanil and saline condition were determined
for the EVs relating to each of the mild and strong anticipation and
loading conditions for each participant using a ﬁxed eﬀects analysis. This
enabled contrasts between the diﬀerent EVs to be created (see
Supplementary Fig. 2). The resulting contrasts were fed into a third-level
mixed eﬀects analysis in order to obtain group averages. FMRIB's Local
Analysis of Mixed Eﬀects (FLAME 1+2 (Woolrich et al., 2004b)) was used
to process images with automatic outlier de-weighting. EVs of no interest
were the sedation score from the Bond-Lader mood scale, order of drug
administration (i.e. whether participants received remifentanil or saline
during their ﬁrst FMRI session), and the mean diﬀerence in unpleasant-
ness score between remifentanil and saline for each subject. CBF values
obtained from the ASL (or diﬀerence in case of the saline remifentanil
contrast) were included as a voxel-wise regressor of no-interest to account
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for remifentanil-induced perfusion changes (Pattinson et al., 2009).
Analysis was corrected for multiple comparisons across the whole brain.
A cluster threshold of > 2.3 and a corrected cluster signiﬁcance threshold
of p=0.05 were used.
To test our hypothesis that opioid action in the amygdala and
hippocampus modulates associative learning, a small volume corrected
non-parametric region-of-interest (ROI) analysis was conducted using
FSL's Randomize tool (Winkler et al., 2014), cluster corrected with Z >
2.3 and p < 0.05. Analysis was conﬁned to a single bilateral mask of the
hippocampus and amygdala (Harvard Oxford Subcortical Atlas thre-
sholded at 50%), to investigate whether the anticipation of strong
loading ( > breathlessness) correlates with remifentanil-induced
changes in unpleasantness scores.
Mild loading condition
The mild stimulus was inconsistently rated; some subjects found it
aversive and became conditioned to the stimulus, whereas for others it
was imperceptible. As we were interested in consistently conditioned
stimuli for this study, data from the anticipation of mild loading is not
reported. Therefore the discussion focuses on the results of the experi-
mental breathlessness induced during the strong loading condition.
ASL analysis
Generation of blood-perfusion maps
Blood ﬂow velocities for the left and right carotid arteries were
extracted from the phase contrast scan with a custom-written MatLab
script. Both arteries showed a 20% perfusion increase with remifentanil
compared to saline (from 31 l/s to 36 l/s, p=0.005). This was used as a
correction factor in the ASL analysis (Aslan et al., 2010).
Multi-TI ASL data was corrected for physiological noise using
RETROICOR (Glover et al., 2000) with a custom-written script that
corrected multi-TI data by separating the time points by TI and by tag
and control condition, before combining them back together. A
quantitative perfusion map was generated for each session with a
custom-written MatLab script that ran registration with FLIRT (FSL
software library) and estimation of CBF with BASIL (Bayesian
Inference for Arterial Spin Labeling MRI; a toolbox of FSL) (Okell
et al., 2013). The resulting voxel-wise CBF averages for each session
were incorporated into higher-level FMRI analyses to help account for
any confounding eﬀects of global CBF changes with remifentanil on the
BOLD signal (Pattinson et al., 2009).
Results
Behavioural and physiological data
Table 1 illustrates respiratory parameters and pulse rate.
Importantly, this demonstrates successful conditioning to the breath-
lessness (strong loading) condition by virtue of a small but signiﬁcantly
increased mouth pressure amplitude during anticipation of the strong
stimulus compared with baseline. This represents increased respiratory
eﬀort. As expected, remifentanil induced mild respiratory depression
(raised baseline PETCO2 and decreased respiratory mouth pressure).
Blood pressure was unchanged between saline (systolic 124( ± 13)
mmHg, diastolic 68( ± 8) mmHg) and remifentanil (systolic 126( ± 13)
mmHg, diastolic 68( ± 10) mmHg), p=0.79 (systolic), p=0.91 (diasto-
lic)). Resting heart rate (obtained from blood pressure cuﬀ between
scans) was unchanged: saline 67( ± 11) min−1, remifentanil 65( ± 7)
min−1, p = 0.35. Oxygen saturations were as follows: saline 98( ± 1),
remifentanil 99( ± 1), p = 0.13. Importantly, no episodes of hypoxae-
mia were noted at any point in the study. Continuous heart rate data
(from the pulse oximeter) was unavailable during scanning on 4
occasions (2 remifentanil, 2 saline, in diﬀerent subjects) therefore the
heart rate data presented in Table 1 is from the 15 subjects with
complete data sets.
Subjective ratings of perceived intensity and unpleasantness of
respiration across stimuli conﬁrmed the successful induction of breath-
lessness (Table 1). Remifentanil signiﬁcantly reduced unpleasantness
scores during strong loading (saline vs. remifentanil: 61.2 ( ± 31.6) vs.
48.7 ( ± 26.2); p = 0.03), but not during unloaded breathing (saline vs.
remifentanil: 10.4 ( ± 17.9) vs. 6.6 ( ± 11.0); p=0.13) (Fig. 2). However,
remifentanil did not signiﬁcantly change breathlessness intensity
during unloaded breathing (saline vs. remifentanil (mean VAS%: 11.9
( ± 16.1) vs. 10.8 ( ± 14.0); p = 0.22) or strong loading (saline vs.
remifentanil: 70.5 ( ± 19.5) vs. 67.5 ( ± 20.2); p = 0.21).
The Bond-Lader mood scales demonstrated greater sedation during
remifentanil infusion (interaction eﬀect, df=1, F = 19.799, p < 0.0001).
There was also an interaction eﬀect showing reduced tension (df=1,
F=15.732, p = 0.001) and reduced discontentment (df=1, F=7.748,
p=0.012; all Bonferroni corrected, signiﬁcant when p < 0.0125) during
the remifentanil condition (see Supplementary Fig. 3). The diﬀerence
in perceived intensities between the saline and remifentanil conditions
positively correlated with perceived unpleasantness (r = 0.589,
p = 0.008), but did not correlate with changes in sedation
Table 1
Effects of resistive load breathlessness on respiratory parameters. PETCO2=partial pressure of end-tidal carbon dioxide. PETO2=partial pressure of end-tidal oxygen.
Saline Remifentanil
Variable Anticipation
unloaded
Unloaded
breathing
Anticipation
breathlessness
Strong
loading
Anticipation
unloaded
Unloaded
breathing
Anticipation
breathlessness
Strong
loading
Mouth pressure
amplitude [cmH2O]
2.7 (0.7) 2.4 (0.5) 3.5 (1.7)¶ 12.7 (4.1)* 2.2 (0.5) 2.0 (0.4) 2.8 (1.0)Δ 10.9 (3.4)*
PETCO2 [kPa] 5.5 (0.6) 5.6 (0.6) 5.5 (0.5) 5.5 (0.6) 6.0 (0.6)
* 6.1 (0.6)* 6.0 (0.6)* 6.0 (0.6)*
PETO2 [kPa] 20.0 (0.9) 19.8 (0.8) 19.9 (0.7) 20.2 (0.8) 20.1 (1.1) 19.8 (1.0) 19.9 (0.9) 20.3 (1.2)
Intensity rating [%VAS] 12(16) 71(20)* 11(14) 68(20)§*
Unpleasantness rating
[%VAS]
10(18) 61(32)* 7(11) 49(26)*§†
Heart rate [min-1]
(N=15)
68 (11) 67 (10) 68 (11) 69 (11) 68 (11) 65 (10) 69 (11) 66 (9)
Values are presented as mean (SD). N=19.
Complete heart rate data in each epoch only available for 15 subjects.
* Signiﬁcantly diﬀerent from saline unloaded breathing at p < 0.001.
§ Signiﬁcantly diﬀerent from remifentanil unloaded breathing at p < 0.001.
† Signiﬁcantly diﬀerent from saline breathlessness at p < 0.05.
¶ Signiﬁcantly diﬀerent from saline anticipation unloaded breathing at p < 0.05.
Δ Signiﬁcantly diﬀerent from remifentanil anticipation unloaded breathing at p < 0.05.
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(r = −0.086, p = 0.73), tension (r = 0.511, p = 0.026) or discontent-
ment (r = 0.319, p = 0.18), all Bonferroni corrected (signiﬁcant when
p < 0.0125; see Supplementary Fig. 3).
Baseline psychological questionnaires
All participants scored within the normal range for trait anxiety
(STAI-T mean: 7, SD ± 6, range (23–57)) and depression (CES-D
mean: 34, SD ± 9, range (0–23)). Thus, no participants were excluded
due to undiagnosed anxiety or depressive disorder.
FMRI results
Conditioned anticipatory response
Saline. Anticipation of the strong resistive inspiratory load (contrast:
strong cue – unloaded cue) increased BOLD signal in the right anterior
insula and operculum, supplementary motor cortex and superior
frontal gyrus, and left cerebellum (Crus I, II, VI, VII and vermis).
Deactivations were observed in the right hippocampus and temporal
gyrus, left precuneus, posterior cingulate cortex and bilateral primary
motor and sensory cortices (Fig. 3).
Saline vs remifentanil. During anticipation (contrast: strong cue -
unloaded cue), there were no signiﬁcant mean changes in BOLD
activity as a result of remifentanil administration.
Remifentanil-induced changes in unpleasantness. Activity within the
bilateral anterior hippocampus and right amygdala correlated with the
remifentanil-induced changes in unpleasantness scores across subjects
during anticipation (contrast: strong cue – unloaded cue), within the
bilateral ROI of the amygdala and hippocampus (Fig. 4).
Breathlessness
Saline. Mean increases in BOLD activity during breathlessness was
observed in the bilateral dorsolateral prefrontal cortex, insula,
operculum, anterior cingulate cortex, supplementary motor cortex,
primary motor and sensory cortices, supramarginal gyrus, superior
parietal lobule, amygdala, thalamus, caudate nucleus, caudal portion of
the periaqueductal gray, pons and cerebellum (Crus I, VI, VII, VIII)
(Fig. 5). Mean decreases in BOLD activity were observed in the
ventromedial prefrontal cortex and precuneus.
Saline vs. remifentanil. Mean decreases in BOLD activity as a result of
remifentanil administration were observed within the cortical network
associated with breathlessness during the saline condition. These areas
included bilateral insula, operculum, anterior cingulate cortex,
supplementary motor cortex, primary motor and sensory cortices,
supramarginal gyrus, thalamus, pons and cerebellum (left Crus I and
VI) (Fig. 5). No increases in BOLD activity were observed during
breathlessness as a result of remifentanil administration compared to
the saline condition.
Remifentanil-induced changes in unpleasantness. A network of areas
that were anti-correlated with the remifentanil-induced decreases in
breathlessness unpleasantness were identiﬁed, i.e. remifentanil-
induced decreases in breathlessness unpleasantness were matched
with corresponding increases in BOLD activity (Fig. 4). These areas
included the rostral anterior cingulate cortex, nucleus accumbens,
ventromedial prefrontal cortex, precuneus, posterior cingulate cortex,
supramarginal gyrus and cerebellum (right VI).
Arterial spin labeling
Remifentanil increased global grey matter cerebral blood ﬂow by
approximately 10% compared to saline (saline grey matter CBF=40.7
(4.4) ml/100 g/min, remifentanil grey matter CBF= 44.8 (4.2) ml/
100 g/min, p=0.003).
Discussion
Key ﬁndings
Remifentanil signiﬁcantly reduced the unpleasantness but not the
intensity of breathlessness, indicating the ability of low-dose opioids to
dissociate breathlessness intensity from unpleasantness.
Conditioned anticipation of breathlessness was associated with
brain activity in areas including the right anterior insula and oper-
culum, supplementary motor cortex and superior frontal gyrus. In the
amygdala and hippocampus, remifentanil suppressed anticipation-
evoked neural activity, which correlated positively with reduction of
breathlessness unpleasantness.
Increased activity was observed during breathlessness in several
brain areas including the bilateral dorsolateral prefrontal cortex,
insula, anterior cingulate cortex, amygdala, thalamus, pons and areas
of the periaqueductal gray. Remifentanil suppressed activity within the
neural network associated with breathlessness, including the insula,
anterior cingulate cortex, thalamus, primary sensory and motor
cortices and pons.
Furthermore, during breathlessness remifentanil induced decreases
in unpleasantness correlated with increases in activity in areas such as
the rostral anterior cingulate cortex (rACC) and nucleus accumbens.
Fig. 2. Breathlessness intensity and unpleasantness scores (on a visual-analogue scale of
0–100%) during unloaded breathing and breathlessness during both saline and
remifentanil (Remi) administration. Bars represent group mean, and error bars standard
deviation. *Signiﬁcantly diﬀerent between the groups (p < .05).
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Fig. 3. BOLD activation contrasting anticipation of breathlessness with anticipation of no loading during saline administration. The image consists of a color-rendered statistical map
superimposed on a standard (MNI) brain. Signiﬁcant regions are displayed with a threshold of Z > 2.3 with a cluster probability threshold of p < 0.05 (corrected for multiple
comparisons). Abbreviations: ant insula, anterior insula; OP, opercular-frontal cortex (operculum); SMC, supplementary motor cortex; SFG, superior frontal gyrus; PC, precuneus; hipp,
hippocampus; M1, primary motor cortex. No signiﬁcant reductions in anticipation of loading were observed with the administration of remifentanil (not shown).
Fig. 4. BOLD activity corresponding with remifentanil-induced decreases in unpleasantness scores across subjects. Top: Increases in BOLD activity with remifentanil that negatively
correlate with decreases in breathlessness unpleasantness, with a graphical depiction of the contrast of parameter estimate (COPE) from the signiﬁcant activity in the rostral ACC plotted
against the decrease in unpleasantness scores. Bottom: Decreases in BOLD activity with remifentanil that correlate with decreases in unpleasantness during anticipation of strong
loading in the hippocampus and amygdala, with a graphical depiction of the contrast of parameter estimate (COPE) from the combined signiﬁcant activity plotted against the decrease in
unpleasantness scores. The image consists of a color-rendered statistical map superimposed on a standard (MNI) brain. The bright gray region delineates the region of interest analysed.
Abbreviations: ACC, anterior cingulate cortex; NA, nucleus accumbens; paraCC, paracingulate cortex; prefrontal cortex; PC, precuneus; amyg, amygdala; ant hipp, anterior
hippocampus.
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Anticipation of breathlessness
It is recognized that anticipation triggers a set of neural events that
primes and inﬂuences the response to the upcoming aversive stimuli.
In our study, anticipation of breathlessness increased the activity in the
right insula and the adjacent operculum. The anterior insula is
functionally associated with emotional processing and self-awareness
(Craig, 2009) and is one of the most commonly activated regions
during anticipation of aversive stimuli. It is thought to facilitate the
detection of saliency and mediate the anticipatory eﬀects on aversive
stimuli (Atlas et al., 2010; Palermo et al., 2015; Ploner et al., 2010).
Based on the present data, we speculate that the anterior insula fulﬁlls
the same role in breathlessness.
Opioid eﬀects on anticipation
We observed an opioid-induced activity reduction in the amygdala
and hippocampus during the anticipation period, which correlated with
a reduction of breathlessness unpleasantness. The amygdala is a key
player in emotional processing of aversive stimuli and is implicated in
conditioned aversive learning (Phelps and LeDoux, 2005). Its interac-
tion with the hippocampus, a structure pivotal for memory consolida-
tion (Eichenbaum and Lipton, 2008), has been shown to enhance the
encoding and consolidation of the learned association between neutral
(anticipatory cues) and aversive stimuli in the hippocampus (LaBar
et al., 1995; Phelps, 2004). Furthermore, these areas are rich in
endogenous opioids and play a role in many other opioid-related tasks
including reward processing (Sesack and Grace, 2010) and opioid
mediated analgesia (Favaroni Mendes and Menescal-de-Oliveira, 2008;
McGaraughty and Heinricher, 2002). The endogenous opioid system
plays a key role in forming associations between neutral stimuli and
aversive stimuli; opioid agonists attenuate and antagonists facilitate
the acquisition of such associations (Eippert et al., 2008; Fanselow,
1998; McNally et al., 2004). We found that opioid suppression of
breathlessness unpleasantness is related to the opioid induced sup-
pression of activity in the amygdala and hippocampus during the
preceding anticipatory cue. Therefore, it is conceivable that opioid
relief of chronic breathlessness stems (at least in part) from functional
interference of neural activity in brain areas that regulate emotional
and memory functions related to breathlessness anticipation.
Brain activations during breathlessness
We identiﬁed a network of areas activated during breathlessness
(Fig. 5) in line with previous published work (Herigstad et al., 2011;
Pattinson and Johnson, 2014). This includes the dorsolateral prefron-
Fig. 5. BOLD activity during the breathlessness condition during saline (placebo) infusion (top ﬁgure) and the eﬀect of remifentanil infusion (lower ﬁgure). The image consists of a
color-rendered statistical map superimposed on a standard (MNI) brain. Signiﬁcant regions are displayed with a threshold of Z > 2.3 and a cluster probability threshold of p < 0.05
(corrected for multiple comparisons). Abbreviations: dlPFC, dorsolateral prefrontal cortex; OFC, opercular-frontal cortex (operculum); ACC, anterior cingulate cortex; M1/S1 primary
motor and sensory cortices; SMG, supramarginal gyrus; Thal, thalamus.
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tal cortex, anterior cingulate cortex, insula, amygdala and the caudate,
areas that are known to represent cognitive and emotional responses to
aversive stimuli (Wiech et al., 2008; Wiech and Tracey, 2009), as well
the motor and sensory cortices most likely representing the motor
response and sensory intensity of breathlessness (Hayen et al., 2012).
These ﬁndings further support the growing concept that perception of
breathlessness is a multi-dimensional sensory experience (De Peuter
et al., 2004; Janssens et al., 2009) encompassing sensory, cognitive and
aﬀective dimensions. Remifentanil suppressed activity in selected
regions representing all the three domains. Remifentanil suppressed
breathlessness-induced activity in the pons, an area known to contain
nuclei of respiratory control (Pattinson, 2008), and further work using
brainstem focused sequences would be merited to understand this in
more depth (Faull et al., 2015, 2016).
Remifentanil-induced suppression of unpleasantness of breathless-
ness was associated with increased activity in the rACC, and nucleus
accumbens. The rACC is part of the endogenous opioid system (Jones
et al., 1991) with a well-documented role in modulating the perception
of aversive stimuli in response to exogenous opioids as well as in
response to cognitive manipulations (Eippert et al., 2009; Petrovic
et al., 2002). PET imaging has shown that increased opioidergic activity
in rACC and the nucleus accumbens reduced the aﬀective and the
sensory perception of a sustained aversive stimulus (Zubieta et al.,
2001). Therefore, it is likely that opioids reduced the unpleasantness of
the breathlessness by engaging the rACC and nucleus accumbens,
structures of the endogenous opioid system that have been shown to
modulate the unpleasantness of other aversive stimuli, such as pain.
Opioid eﬀects on physiological measures of respiration
Infusion of remifentanil was associated with mild respiratory
depression; a well-known eﬀect of opioids (Mitsis et al., 2009;
Pattinson, 2008; Pattinson et al., 2007). However, we observed a
signiﬁcantly increased mouth pressure amplitude during anticipation
of breathlessness when compared with anticipation of no load for both
saline and remifentanil conditions. This suggests that the conditioned
increase in ventilation in response to the anticipatory cue was main-
tained during both conditions. This behavioural ﬁnding is in accor-
dance with maintained mean BOLD activity during anticipation. Based
on our data showing suppression of activity in emotion processing
areas, we speculate that low dose opioids dissociate respiratory and
emotional eﬀects whilst maintaining the conditioned ventilatory an-
ticipatory response.
Opioid eﬀects upon emotional state
During remifentanil infusion, participants were in a more positive
emotional state, reporting reduced tension and discontentment and
increased sedation. Opioids cause a generalized positive shift in aﬀect
across the hedonic spectrum, from enhancing the pleasantness of food
to decreasing perceived pain (Leknes and Tracey, 2008). By accounting
for these factors in our FMRI analysis, we are conﬁdent that the
observed BOLD changes were speciﬁc to breathlessness and its
anticipation.
Clinical relevance
Our ﬁndings demonstrate how studies performed in healthy
volunteers help probe mechanisms that might otherwise be diﬃcult
to isolate in clinical populations. A recent FMRI study in COPD
(Herigstad et al., 2016, 2015) demonstrated brain activations in the
insula, prefrontal cortices, operculum and striatum in response to
breathlessness-related word cues. The authors speculated that these
activations might relate to a learned or conditioned response. The
present study adds weight to that speculation by demonstrating
similarities in the anticipatory brain activation pattern (during saline
infusion) in an experiment in which conditioned learning was speciﬁ-
cally induced to model aspects of chronic breathlessness.
There is an unmet clinical need for new treatments for chronic
breathlessness (Currow et al., 2016). Targeting associative learning
represents an untapped potential for new treatments. The present data
demonstrates that conditioned anticipatory activity is mediated by the
anterior insula, one of the key brain structures associated with emotion
regulation (Craig 2009). In health, anticipatory brain activity is a
beneﬁcial adaptation to avoid danger and suﬀering (Ley, 2001), but if
overexpressed may lead to unhealthy deconditioning, activity avoid-
ance, worsening quality of life and worsening breathlessness (Hayen
et al., 2013). Opioid eﬀects on associative learning might explain how
low-dose opioids may have gradual increases in eﬃcacy over the ﬁrst
week of administration (Currow et al., 2013; Oxberry et al., 2013).
Opioid side eﬀects are well described (Pattinson, 2015; Ray et al.,
2016; Robertson et al., 2016; Vozoris et al., 2016), with death due to
respiratory depression particularly feared. An in-depth understanding
of their mechanisms of action will pave the way to safer alternatives.
Additionally, maladaptive learning is starting to be recognized as an
important factor in chronic pain, with generalization of negative
emotions over sensory discrimination contributing to chronicity
(Zaman et al., 2015). Health anxiety often co-exists with disease,
exacerbating symptoms and morbidity. The importance of this has only
recently been realized in mainstream medical journals (Tyrer et al.,
2016). It is likely that such mechanisms play a similarly important role
in chronic breathlessness, where they could mediate the disease
trajectory by initiating and fuelling fear, activity avoidance and
deconditioning.
Discussion of methods
Respiratory manipulations and opioid infusions may confound the
interpretation of BOLD FMRI (Pattinson and Wise, 2016). Therefore,
we have included a number of steps in the study design and analysis to
address these potential confounds. These are discussed below and in
more detail in the Supplementary material.
Control of end-tidal gases
Inspiratory resistive loading may alter PETCO2 (Hayen et al., 2015),
which confounds interpretation of BOLD responses (Cohen et al., 2002;
Wise et al., 2007). Respiratory depression caused by remifentanil may
also lower oxygen saturations, again potentially confounding BOLD.
Therefore, we manually controlled both PETCO2 and PETO2 on a breath-
by-breath basis to minimise stimulus-correlated ﬂuctuations. To do
this, it was necessary to perform the experiment upon a baseline of
mild hypercapnia (+0.3 kPa above baseline), and mild hyperoxia
(PETO2 of 20 kPa). The caveat with this approach is that this mild
hypercapnia and hyperoxia will slightly reduce BOLD responsiveness
overall, and is thus conservative.
The use of ASL to account for between-session diﬀerences in CBF
Remifentanil depresses respiration (Mitsis et al., 2009), leading to
hypercapnia and increased baseline CBF (MacIntosh et al., 2008).
Voxel-wise measures of CBF were incorporated as a covariate, allowing
for diﬀering eﬀects of baseline CBF on BOLD response across the brain
(Pattinson et al., 2009), thus accounting for additive or subtractive
diﬀerences in stimulus-evoked BOLD response. An important caveat of
this technique is that it assumes a linear eﬀect of CBF on baseline
BOLD and a more complex relationship between CBF and stimulus-
evoked BOLD might not be accounted for.
Accounting for potential changes in the haemodynamic response
The haemodynamic response function (HRF) varies between brain
regions and individuals (Handwerker et al., 2004), and may be inﬂuenced
by varying levels of neurotransmitters (Muthukumaraswamy et al., 2012),
and by exogenously administered drugs (Luchtmann et al., 2010).
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Therefore, instead of using the ﬁxed standard gamma waveform, we used
an optimal basis set of three waveforms (FLOBS: FMRIB's Linear Optimal
Basis Sets, default FLOBS supplied in FSL (Woolrich et al., 2004a)).
Although this approach may more accurately account for varying HRFs, it
may lead to a small underestimation of the eﬀect size.
Physiological noise correction
The main sources of physiological noise in FMRI relate to the
respiratory and cardiac cycle (Brooks et al., 2013; Glover et al., 2000;
Harvey et al., 2008). These were corrected using RETROICOR and ICA-
based noise classiﬁcation. Whilst cleaning imaging data of unwanted
noise, the main caveat for noise correction in general is that any neural
signals that are aliased to the cardiac and respiratory cycles will be lost.
RETROICOR uses continuous measures of cardiac and respiratory
cycles during a scan to regress out these known quantities. It requires
hardware investment and technical expertise at the time of scanning.
Lost signal (e.g. a poor pulse oximeter trace) cannot be retrospectively
accounted for. ICA decomposition requires training data which has to
be classiﬁed manually, which is time consuming and can be subject to
experimenter bias. In the present study, the person who did the ICA
classiﬁcation was blinded to experimental condition. The beneﬁt of
using a combination of RETROICOR and ICA decomposition is a
comprehensive noise correction, but this has the caveat of requiring an
even more complex analysis to ensure that noise is not reintroduced.
Conclusions
Anticipation of cues associated with breathlessness activates the
right anterior insula and the adjacent operculum, brain regions
implicated in aversive conditioning and emotional regulation.
Remifentanil suppressed the neural activity during the anticipatory
period in the amygdala and hippocampus, regions implicated in
aversive memory formation, which was expressed as reductions in
unpleasantness of breathlessness. Furthermore, during remifentanil
infusion, reductions in breathlessness unpleasantness correlated with
increases in activity in the rACC and nucleus accumbens, well-
established components of the endogenous opioid system known to
decrease the perception of aversive stimuli. These ﬁndings suggest that
opioids palliate breathlessness through an interplay of altered associa-
tive learning mechanisms, independent of or in addition to eﬀects on
brainstem respiratory control. These provide potential targets for novel
or improved behavioural or pharmacological treatments to break the
well-known spiral of decline in order to ease daily suﬀering of people
with chronic breathlessness.
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